MedTrace Logo

HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer

NCT06389500 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-04-29

No results posted yet for this study

Summary

This is a single-arm, exploratory, phase II trial to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy combined with adebrelimab and lenvatinib for borderline resectable, locally advanced biliary tract cancer.

Conditions

  • Biliary Tract Cancer

Interventions

DRUG

Adebrelimab

Adebrelimab, IV

DRUG

Lenvatinib

Lenvatinib, PO

PROCEDURE

Hepatic Arterial Infusion Chemotherapy

GC regimen±5-FU

Sponsors & Collaborators

  • Harbin Medical University

    lead OTHER

Principal Investigators

  • Yubao Zhang, MD · Harbin Medical University Affiliated Cancer Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-01
Primary Completion
2027-05-01
Completion
2028-05-01

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06389500 on ClinicalTrials.gov